Crossmark

Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway

Crossref DOI link: https://doi.org/10.1016/j.omtn.2019.01.015

Published Print: 2019-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gu, Chunming

Liu, Yanjun

Yin, Zhao

Yang, Juhua

Huang, Guiping

Zhu, Xuejiao

Li, Yumin

Fei, Jia
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81170496)

Research Project for Practice Development of National TCM Clinical Research Bases (JDZX2015119)

Science and Technology Program of Guangdong Province (2014A020212729, 2016A020226027)

Science and Technology Program of Guangzhou City (201504281729050)

Fundamental Research Funds for the Central Universities (17817021)
License Information

Text and Data Mining valid from 2019-06-01

Text and Data Mining valid from 2019-06-01

Version of Record valid from 2019-02-05
More Information

This article is maintained by: Elsevier

Article Title: Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway

Journal Title: Molecular Therapy - Nucleic Acids

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.omtn.2019.01.015

Content Type: article

Copyright: © 2019 The Authors.